TroFuse-015 met its overall survival primary endpoint for sacituzumab tirumotecan versus treatment of physician's choice in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior lines, claimed as the first global Phase 3 overall survival benefit for a TROP2-directed antibody-drug conjugate in this population. [1][2] That randomized Phase 3 tier outweighs early TROP2 activity from single-arm Phase 1b/II sacituzumab govitecan in metastatic esophagogastric adenocarcinoma with enrollment 67 and the Phase 3 MK-2870 versus treatment of physician's choice register entry with enrollment 473 listing trifluridine-tipiracil, irinotecan and paclitaxel. [1][3] Contextual non-TROP2 benchmarks show what concordant wins looked like: DESTINY-Gastric01 reported objective response rate 40.5% versus 11% with overall survival 12.5 versus 8.4 months, RAINBOW reported overall survival 9.63 versus 7.36 months with progression-free survival 4.4 versus 2.86 months, and TAGS established trifluridine-tipiracil as third-line standard. [4] No hazard ratios, medians, confidence intervals, response percentages, duration of response, subgroup or safety rates were disclosed for sac-TMT, and progression-free survival was not met with only nominally improved response. For payers, existing options carry MCBS scores of 2 for ramucirumab-paclitaxel and 1 for ramucirumab monotherapy, so added benefit cannot be judged. No closely comparable precedent exists sharing both TROP2 mechanism and this Phase 3 refractory context, so filing rests on overall survival magnitude still to be shown and explanation for discordant progression-free survival remains the gating risk. [5]
Global Phase 3 OS met versus TPC but PFS missed, ORR only nominal, with no HRs, medians or safety rates disclosed. [1]
| Indication | Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (third-line or later) |
| Drug | Sacituzumab tirumotecan |
| Mechanism of Action | TROP2-directed antibody-drug conjugate |
| Company | Merck |
| Trial Phase | Phase 3 |
| Trial Acronym | TroFuse-015 |
| NCT ID | NCT06356311 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Primary Endpoint Met | Overall Survival (OS) |
| Secondary Endpoint Not Met | Progression-Free Survival (PFS) |
| Secondary Endpoint Nominally Improved | Objective Response Rate (ORR) |
| Comparator Arm | Treatment of Physician’s Choice (TPC) |
| Patient Enrollment | 473 patients |
| Line of Therapy | Third-line or later |
| Licensing Partner | Kelun-Biotech |
| Licensed Territory | All territories outside of Greater China (Mainland China, Hong Kong, Macau and Taiwan) |
| Regulatory Next Steps | Data to be presented at upcoming medical meeting and shared with regulatory authorities |
| TROP2 Expression Status | Consistent across subgroups regardless of TROP2 expression status |
Merck's Sacituzumab Tirumotecan Improves OS in Advanced Gastroesophageal Cancer
Merck announced that its pivotal Phase 3 TroFuse-015 trial, evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, met its primary endpoint of overall survival (OS). The trial compared sac-TMT to treatment of physician’s choice (TPC) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received two or more prior lines of systemic therapy. This marks the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 study for this patient population, addressing a significant unmet medical need. Sac-TMT showed a statistically significant and clinically meaningful improvement in OS. While the secondary endpoint of progression-free survival (PFS) was not met, objective response rate (ORR) showed a nominally improved benefit. The safety profile was consistent with previous observations.
- Sacituzumab tirumotecan (sac-TMT) achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who had received two or more prior lines of systemic therapy. This represents a first-in-class OS benefit for a TROP2-directed ADC in this challenging patient population.
- The Phase 3 TroFuse-015 trial, a randomized, open-label, multicenter, global study, enrolled 473 patients. While the primary endpoint of OS was successfully met, the secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR) was not. However, a nominally improved benefit was observed for objective response rate (ORR), another secondary endpoint, favoring sac-TMT.
- TroFuse-015 is the second positive Phase 3 readout from Merck’s extensive TroFuse clinical development program for sac-TMT, which currently encompasses 18 ongoing global Phase 3 trials. This program is evaluating sac-TMT across a broad range of tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers, spanning early-to-late-stage disease as both monotherapy and in combination with immunotherapies.
Addressing the Unmet Need in Advanced Gastroesophageal Adenocarcinoma
Management of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma beyond second-line remains constrained by diminishing efficacy and evolving tumor biology. Although several chemotherapies, targeted agents and immunotherapies have been investigated, there is no guideline on third-line therapy available for clinicians.
Failure of anti-HER2 strategies beyond progression: Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Loss of HER2 positivity and loss of HER2 over-expression was observed in 32 and 32% samples, respectively, after trastuzumab-based chemotherapy, which may be one of the biological reasons explaining the failure of anti-HER2 second-line strategies in initially HER2-positive disease.
Tumor heterogeneity and assessment variability: Variable HER2 amplification assessment, tumour heterogeneity, and microenvironmental factors could limit the effectiveness of anti-HER2 blockade. Matched biopsy and resection analysis showed tumor heterogeneity in 80% of discrepant cases compared with 24% of concordant cases (P = .016), and generous sampling for biopsy specimens is necessary to ensure accurate assessment.
Acquired molecular resistance pathways: The majority of gastric cancer patients who achieve an initial response to trastuzumab-based regimens develop resistance within 1 year of treatment. Reported mechanisms include pathologic activation of Src such as acquired SrcE527K mutation, induction of epithelial-to-mesenchymal transition with HER2 downregulation, and upregulation of fibroblast growth factor receptor 3 (FGFR3) with increased phosphorylated AKT and ZEB1 expression in post-progression biopsies.
Low response and short durability in later lines: Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months for first- to fifth-line treatment, respectively. Longer progression-free survival in previous lines positively influenced prognosis, while third-line treatment intensity and optimal sequencing remain undefined.
Restricted and biomarker-dependent immunotherapy benefit: Durable benefit remains restricted to biologically selected patient subgroups. Biomarker interpretation is limited by assay variability, spatial and temporal heterogeneity, dynamic PD-L1 expression, inconsistent CPS thresholds, overlap between TMB-high and MSI-H biology, and the limited prospective validation of exploratory markers. The intratumoral immune response was suppressed by previous treatments in most third- or later-line nivolumab recipients, and the tumor-infiltrating immune response was compromised by prior treatments in third-line therapy.
TroFuse-015: Design and Pivotal OS Benefit in GEA
In later lines of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, key studies evaluate sequencing of second- and third-line regimens and trifluridine-tipiracil-based combinations after two or more prior lines. Primary endpoints focus on overall survival and progression-free survival, with response, disease control, safety and quality of life as secondary measures.
| Study / Trial | Population and Treatment Line | Design and Arms | Primary Endpoint | Secondary / Other Endpoints |
|---|---|---|---|---|
| Retrospective sequencing study in metastatic GA patients who received at least 3 lines of therapy | 94 patients available for analysis (51 pts group A; 43 pts group B) | Group A: RAM/PAC second-line with FOLFIRI/CAPEIRI third-line vs Group B: FOLFIRI/CAPEIRI second-line followed by RAM/PAC | Overall survival (OS) | Median OS from start of second-line therapy (group A = 10.5 months vs group B = 11.1 months, p = 0.97) and median OS from metastatic disease diagnosis (group A = 19.8 months vs group B = 19.4 months, p = 0.73) |
| ENGIC 06 - PRODIGE 114 - FFCD 2401 - FRUQUITAS | Metastatic oesophageal, gastro-oesophageal junction or gastric adenocarcinoma previously treated with two or three treatment lines | International, multicentre, open-label, randomized phase III comparing trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil alone, randomized 1:1 and stratified by treatment line, time from metastatic diagnosis to randomization, WHO performance status and prior anti-angiogenic exposure | Overall survival | Progression-free survival, time to progression, objective response rate, disease control rate, safety, quality of life and translational biomarker analyses |
| Randomized Phase 2 trial in previously treated metastatic GEA | 103 patients included in the trial, with plasma samples available in 86 patients | Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil alone, with plasma collected at baseline and during treatment (weeks 4 and 8) | Survival outcomes evaluated by baseline ctDNA levels and early ctDNA changes assessed by ctDNA-RECIST | Progression-free survival (median 1.8 vs 4.6 months; HR 2.2, p = 0.005 for highest baseline ctDNA) and overall survival (median 5.5 vs 9.9 months; HR 2.2, p = 0.004) |
| Prospective study of apatinib combined with or without chemotherapy | 175 patients with chemotherapy-refractory advanced and metastatic gastric or metastatic gastroesophageal junction adenocarcinoma, refractory to 1 or more line of prior chemotherapy | Prospectively enrolled and assigned 2:1 to combination group (apatinib + chemotherapy) versus chemotherapy alone group; apatinib dose 500 mg/d, chemotherapy regimens based on fluoropyrimidine, platinum, and paclitaxel or irinotecan | Progression-free survival (PFS) | Disease control rate (58.4% vs 41.9%, P = .041); PFS 8.5 months [95% CI, 6.45-10.54] vs 7.0 months [95% CI, 5.12-8.88] P = .021; hazard ratio 0.645 [95% CI: 0.429-0.969] P = .035 |
Sac-TMT's Broad Potential Across Multiple Tumor Types
Sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, has demonstrated promising clinical activity in breast and lung cancer and is currently under evaluation across urothelial, gynecologic, and other solid tumors. Trials span monotherapy dose-expansion, randomized comparisons versus chemotherapy or docetaxel, and combinations with PD-1/PD-L1 inhibitors including pembrolizumab and tagitanlimab.
| Indication | Study / Trial | Intervention Model |
|---|---|---|
| Advanced or metastatic urothelial carcinoma with progression on ≥1 prior platinum-based chemotherapy and anti‒PD-(L)1 therapy | 2870-001/KL264-01 cohort 9 | sac-TMT 5 mg/kg intravenously every 2 weeks monotherapy until disease progression, unacceptable toxicity, or participant/physician decision |
| Previously treated, advanced NSCLC with or without activating EGFR mutations | KL264-01 (n = 43) and SKB264-II-08 (n = 64 EGFR-mutant) | sac-TMT single-agent activity; EGFR-mutant subset evaluated |
| EGFR-mutated locally advanced or metastatic NSCLC after EGFR-tyrosine kinase inhibitors and platinum based chemotherapy | NCT05631262, 48 centres in China | sac-TMT (5 mg/kg) on days 1 and 15 of each four week cycle versus docetaxel (75 mg/m) on day 1 of each three week cycle; crossover to sac-TMT on progression permitted |
| EGFR-mutated locally advanced or metastatic nonsquamous NSCLC progressed after EGFR-TKI therapy | OptiTROP-Lung04, NCT05870319 | sac-TMT monotherapy versus pemetrexed plus platinum-based chemotherapy, 1:1 randomization |
| Metastatic triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer refractory to standard therapies | MK-2870-001 (KL264-01), NCT04152499 | sac-TMT intravenously every 2 weeks at 2 to 12 mg/kg in dose-escalation; recommended doses for expansion of 4 and 5 mg/kg |
| Locally recurrent or metastatic TNBC with two or more prior therapies, including at least one for metastatic disease | OptiTROP-Breast01, NCT05347134 | sac-TMT (n = 130) versus chemotherapy (n = 133) |
| Previously untreated, locally recurrent unresectable or metastatic TNBC with PD-L1 CPS <10 | TroFuse-011, NCT06841354 | sac-TMT (arm A) versus sac-TMT plus pembrolizumab (arm B) versus treatment of physician's choice (arm C; paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) |
| PD-L1-positive advanced NSCLC without targetable genomic alterations, PD-L1 TPS 1% or greater, first-line | OptiTROP-Lung05, NCT06448312 | sac-TMT (4 mg/kg on days 1, 15, and 29) plus pembrolizumab (400 mg fixed dose on day 1) every 6 weeks versus pembrolizumab alone |
| Advanced or metastatic NSCLC without actionable genomic alterations, first-line | OptiTROP-Lung01, NCT05351788 | Cohort 1A: sac-TMT (5 mg kg, every 3 weeks) plus tagitanlimab (1,200 mg, every 3 weeks); Cohort 1B: sac-TMT (5 mg kg, every 2 weeks) plus tagitanlimab (900 mg, every 2 weeks) |
| Cervical, ovarian, and endometrial cancers | Ongoing phase III trials | Not reported |
| Unresectable locally advanced/metastatic solid tumors refractory to standard therapies | Phase 1 dose-escalation cohorts | sac-TMT by intravenous administration every 2 weeks |
Frequently Asked Questions
References
- [1] Fang W, Li X et al.. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ (Clinical research ed.). 2025 Jun 5. 40473437
- [2] Ouyang Q, Rodon J et al.. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. Journal of hematology & oncology. 2025 Jun 6. 40481574
- [3] Li X, Li X et al.. Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. OncoTargets and therapy. 2018. 30038504
- [4] Zhao S, Cheng Y et al.. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nature medicine. 2025 Jun. 40210967
- [5] Kawaguchi D, Kawakami T et al.. Rare Case of Advanced Gastric Cancer Complicated with Fibrinogen Storage Disease Treated with Chemotherapy plus Immune Checkpoint Inhibitor: A Case Report. Case reports in oncology. 2023 Jan-Dec. 37928864
- [6] Wöll E, Amann A et al.. Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update. Anticancer research. 2023 Jul. 37351962
- [7] Shitara K, Janjigian YY et al.. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nature medicine. 2025 May. 40055521
- [8] Xiong A, Yao W et al.. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England). 2026 Jun 27. 42214392
- [9] Shah MA, Kennedy EB et al.. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Mar 1. 36603169
- [10] Zhang X, Sheng W et al.. Chinese consensus on first-line precision therapy for advanced gastric cancer. Innovation (Cambridge (Mass.)). 2026 Jul 6. 42422023
- [11] Poli De Frias F, Petit RK et al.. Concomitant Use of Steroids and Immunotherapy in a Patient With Paraneoplastic Dermatomyositis and Gastroesophageal Adenocarcinoma. Cureus. 2023 Oct. 38021941
- [12] Peng W, Zhang F et al.. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. Cancer management and research. 2020. 32821164
- [13] Janjigian YY, Shitara K et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England). 2021 Jul 3. 34102137
- [14] Imamura H, Ikeda M et al.. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World journal of gastroenterology. 2006 Oct 28. 17072984
- [15] Wu XQ, Ge YP et al.. [Advances in Treatment of Human Epidermal Growth Factor Receptor 2-Positve Gastric Cancer]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 2022 Oct. 36325789
- [16] Moy RH, Dos Santos Fernandes G et al.. Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The oncologist. 2020 Jan. 31570517
- [17] Xu Z, Ding L et al.. Comparative efficacy of subsequent-line therapies for advanced triple-negative breast cancer: a bayesian network meta-analysis. Oncology reviews. 2026. 42494819
- [18] Guo Y, Tang J et al.. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study. Medicine. 2019 Feb. 30732125
- [19] Moehler M, Högner A et al.. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. European journal of cancer (Oxford, England : 1990). 2022 Nov. 36183651
- [20] Maron SB, Alpert L et al.. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer discovery. 2018 Jun. 29449271
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com











